# Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

> **NCT04221256** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Burke Medical Research Institute**

## Conditions studied

- Stroke, Ischemic

## Interventions

- **DRUG:** Administration of SSRI escitalopram
- **BEHAVIORAL:** Paired Associative stimulation
- **DRUG:** Administration of Placebo

## Key facts

- **NCT ID:** NCT04221256
- **Lead sponsor:** Burke Medical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-11
- **Primary completion:** 2021-02-09
- **Final completion:** 2021-02-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Closure due to COVID-19 pandemic
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04221256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04221256, "Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04221256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*